1. Scrip
  2. >>Business

Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs

Interview With Pharma R&D Head Christian Rommel

 
• By Mandy Jackson

The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.

Christian Rommel
Scrip spoke with Bayer's Christian Rommel during the J.P. Morgan meeting • Source: Bayer

Bayer AG head of pharmaceuticals research and development Christian Rommel acknowledges that the conglomerate is working its way through a difficult period, but he oversees an R&D pipeline that needs more time to show that the company’s investments in technologies like chemoproteomics and cell and gene therapies will pay off. It’s a big ask for investors who have been waiting a while already for Bayer’s strategy to deliver significant returns.

Key Takeaways

  • Bayer is facing a no-growth period for its pharma business at a time when the conglomerate has challenges across all three of its business groups.

“We are in a resilience phase,” Rommel told Scrip in an interview during the J.P. Morgan Healthcare Conference. “We have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

More from Scrip

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.